PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
通过 iNOS 和 COX-2 选择性抑制剂预防 CRC
基本信息
- 批准号:6815750
- 负责人:
- 金额:$ 30.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-23 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:apoptosisbiomarkercancer preventioncarcinogenesiscell growth regulationcell proliferationchemopreventioncolorectal neoplasmscombination chemotherapydisease /disorder modeldosagedrug design /synthesis /productiondrug screening /evaluationenzyme inhibitorsgene expressiongene expression profilinglaboratory ratmaleneoplasm /cancer chemotherapyneoplasm /cancer pharmacologyneoplastic cellneoplastic processnitric oxide synthasenonhuman therapy evaluationprostaglandin endoperoxide synthase
项目摘要
DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop the use of inducible nitric oxide synthase (iNOS)-selective inhibitors in the chemoprevention of colorectal cancer, and to gain an understanding of the cellular and molecular mechanism(s) of tumor inhibition by these agents. In addition, we will design the strategies for improving the efficacy of colon cancer prevention and treatment by concurrent application of iNOS- and COX-2 selective inhibitors. Colorectal cancer is one of the most common human malignancies in the United States, anticipated to account for 140,000 new cases and about 56,000 deaths in the year 2003. Developing treatment strategies, aimed at a specific molecular target that facilitate(s) tumor cell growth, uncontrolled expansion and invasion, provide a rational approach. Nitric oxide, produced by isoforms of NOS, has been implicated in several pathophysiological conditions including colon carcinogenesis. Our studies and those of others indicate that iNOS activities were up-regulated several-fold in colon tumors compared to normal mucosa and, importantly, nitric oxide or its reactive molecules derived from these enzymes play a pivotal role in modulation of apoptosis and proliferation. Recent evidence from our laboratory suggests that iNOS-selective inhibitors suppress chemically-induced colon carcinogenesis and also tumor formation in transgenic APC min mice. Thus, it is important to systematically develop iNOS-selective inhibitors for colon cancer prevention/treatment and delineate the specific mechanisms that lead to inhibition of tumorigenesis by these agents.
Specifically, we will 1) examine the chemopreventive efficacy of different iNOS-inhibitors [PBIT, NILT and BIPPA] on azoxymethane (AOM)-induced colon carcinogenesis in rats (maximum tolerated dose selection; dose-response effects; and effectiveness during promotion/progression stages of colon carcinogenesis; 2) establish strategies to improve efficacy of colon cancer prevention and treatment by a combination of COX-2- and iNOS-selective inhibitors and 3) assess the cellular and molecular biomarkers associated with iNOS inhibition/COX-2 inhibition (apoptotic and proliferation changes, nitric oxide, 3-nitrotyrosine, and expression and activities of isoforms of NOS and COX) and study the modulation of gene expression profiles to identify changes in functional groups of genes associated with apoptosis, cell-cycle regulation and iNOS and COX-2 mediated signals and 4) understand the mechanisms by which inhibitors of iNOS and COX-2 modulate colon tumor cell proliferation and apoptosis.
描述(由申请人提供):本提案的总体目标是开发诱导型一氧化氮合酶(iNOS)选择性抑制剂在结直肠癌化学预防中的应用,并了解这些药物抑制肿瘤的细胞和分子机制。此外,我们将设计通过iNOS-和COX-2选择性抑制剂同时应用来提高结肠癌预防和治疗效果的策略。结直肠癌是美国最常见的人类恶性肿瘤之一,预计2003年将有14万例新病例和约5.6万例死亡。针对促进肿瘤细胞生长、不受控制的扩张和侵袭的特定分子靶点制定治疗策略,提供了一种合理的方法。一氧化氮由一氧化氮的异构体产生,与多种病理生理条件有关,包括结肠癌的发生。我们和其他人的研究表明,与正常粘膜相比,iNOS活性在结肠肿瘤中上调了数倍,重要的是,一氧化氮或由这些酶衍生的活性分子在调节细胞凋亡和增殖中起着关键作用。我们实验室最近的证据表明,在转基因APC小鼠中,inos选择性抑制剂抑制化学诱导的结肠癌发生和肿瘤形成。因此,系统地开发用于结肠癌预防/治疗的inos选择性抑制剂,并描述这些药物抑制肿瘤发生的具体机制是很重要的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chinthalapally V. Rao其他文献
Mutational disparities in colorectal cancers of White Americans, Alabama African Americans, And Oklahoma American Indians
白种美国人、阿拉巴马州非裔美国人和俄克拉何马州美洲印第安人结直肠癌的突变差异
- DOI:
10.1038/s41698-024-00782-9 - 发表时间:
2024-12-23 - 期刊:
- 影响因子:8.000
- 作者:
Hiroshi Y. Yamada;Madhusmita Rout;Chao Xu;Philip H. O’Neill;Farrukh Afaq;Katherine T. Morris;Dharambir K. Sanghera;Upender Manne;Chinthalapally V. Rao - 通讯作者:
Chinthalapally V. Rao
Targeting PGE<sub>2</sub>/IL-23 Nexus in TME for CRC Prevention and Treatment
- DOI:
10.1016/j.canlet.2023.216553 - 发表时间:
2024-01-28 - 期刊:
- 影响因子:
- 作者:
Chinthalapally V. Rao - 通讯作者:
Chinthalapally V. Rao
Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer
- DOI:
10.1007/s10555-011-9311-2 - 发表时间:
2011-10-21 - 期刊:
- 影响因子:8.700
- 作者:
Naveena B. Janakiram;Altaf Mohammed;Chinthalapally V. Rao - 通讯作者:
Chinthalapally V. Rao
Chinthalapally V. Rao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chinthalapally V. Rao', 18)}}的其他基金
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTIO
预防癌症临床前药物开发计划:临床前疗效和终点生物标志物。
- 批准号:
10269136 - 财政年份:2020
- 资助金额:
$ 30.03万 - 项目类别:
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.
评估两类不同类型的化合物(STAT3 抑制剂和 Serms)预防膀胱癌的作用。
- 批准号:
10674662 - 财政年份:2020
- 资助金额:
$ 30.03万 - 项目类别:
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.
评估两类不同类型的化合物(STAT3 抑制剂和 Serms)预防膀胱癌的作用。
- 批准号:
10269139 - 财政年份:2020
- 资助金额:
$ 30.03万 - 项目类别:
ShEEP Request for CTL ImmunoSpot S6 Universal Analyzer
ShEEP 请求 CTL ImmunoSpot S6 通用分析仪
- 批准号:
9795713 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
通过 iNOS 和 COX-2 选择性抑制剂预防 CRC
- 批准号:
6952292 - 财政年份:2004
- 资助金额:
$ 30.03万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
- 批准号:81101308
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
精神分裂症记忆障碍的脑网络组学研究
- 批准号:91132301
- 批准年份:2011
- 资助金额:350.0 万元
- 项目类别:重大研究计划
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
- 批准号:81072363
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
- 批准号:81060151
- 批准年份:2010
- 资助金额:25.0 万元
- 项目类别:地区科学基金项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10475138 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10686370 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10475132 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10686367 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10015216 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10252869 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10252870 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10015217 - 财政年份:2019
- 资助金额:
$ 30.03万 - 项目类别:
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
IGF::OT::IGF 评估间歇性服用阿司匹林预防结直肠癌的效果
- 批准号:
9369089 - 财政年份:2016
- 资助金额:
$ 30.03万 - 项目类别:
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
IGF::OT::IGF 评估间歇性服用阿司匹林预防结直肠癌的效果
- 批准号:
10018590 - 财政年份:2016
- 资助金额:
$ 30.03万 - 项目类别: